...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Great surge in PPS for fellow RVX investers

I agree those numbers ($2B, $3B, 10B) are excessive, even for the entire company.  I am skeptical on the size of any distribution to shareholders as the result of a sale or deal.  I'll take an uninformed wild guess and say something in the $2 or $3 range.  I will be pleased if I'm very wrong. I would be very much opposed to a Contingent Value Rights (CVR) deal if that's what happens -- for the reasons explained in this Forbes article (that I've posted many times before on various boards cause I don't like CVRs).

Share
New Message
Please login to post a reply